Application of p-hydroxy benzylidene acetone in preparation of drugs for preventing and/or treating encephalopathy

A technology of hydroxybenzylidene acetone and medicine, which is applied to the application field of p-hydroxybenzylidene acetone in the preparation of drugs for preventing and/or treating encephalopathy, can solve problems such as inability to infer the prevention and/or treatment of encephalopathy, and achieve anti-cerebral ischemia. and reperfusion injury, excellent curative effect, anti-brain injury effect

Inactive Publication Date: 2012-10-03
GUANGZHOU GENERAL HOSPITAL OF GUANGZHOU MILITARY COMMAND
View PDF7 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0012] At present, there is no report that p-hydroxybenzylideneacetone is used as a brain protective agent, for the prevention and/or treatment of encephalopath

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of p-hydroxy benzylidene acetone in preparation of drugs for preventing and/or treating encephalopathy
  • Application of p-hydroxy benzylidene acetone in preparation of drugs for preventing and/or treating encephalopathy
  • Application of p-hydroxy benzylidene acetone in preparation of drugs for preventing and/or treating encephalopathy

Examples

Experimental program
Comparison scheme
Effect test

Example Embodiment

[0035] Example 1

[0036] The invention relates to an experiment on the effect of p-hydroxybenzylidene acetone on cultured brain nerve cells.

[0037] 1 ,Experimental Materials

[0038] 18 ordinary Sprague Dawley rats weighing 250-280g. Polylysine is a product of Sigma; DMEM medium is a product of Gibco; the rest of the reagents are analytical pure.

[0039] 2. Primary culture of nerve cells

[0040] The pregnant rats were anesthetized with chloral hydrate on the 15th day of pregnancy, and the chest and abdomen were sterilized with 75% ethanol. The fetal rats were taken out under aseptic conditions, peeled off, and the cortical tissues on both sides were separated, cut into a minced dough with a scalpel, and transferred into the 0.125% trypsin After digestion in phosphate buffer for 30 min (37℃), discard the digestion solution, add DMED culture medium containing 10% fetal bovine serum, 10% horse serum, 100U / ml penicillin, 100U / ml streptomycin, and use a small-bore pipette Repeatedl...

Example Embodiment

[0049] Example 2

[0050] This experiment involves the protective effect of p-hydroxybenzylidene acetone on mice with closed brain trauma.

[0051] 1. Experimental equipment

[0052] Automatic recorder for jumping platform experiment, Electric Room of Institute of Medicine, Chinese Academy of Medical Sciences; Fluorescence Spectrophotometer, HITACHI Company, Japan; Microplate reader.

[0053] 2. Experimental animals

[0054] Clean-grade Kunming mice weighing 20-22g.

[0055] 3. Experiment

[0056] Take 60 mice and randomly divide them into six groups: (1) normal control group; (2) model group; (3) p-hydroxybenzylidene acetone 1 mg / kg (diluted with 5% glucose injection to the appropriate level when using the drug) Concentration) group; (4) p-hydroxybenzylidene acetone 2 mg / kg group; (5) p-hydroxybenzylidene acetone 4 mg / kg group; (6) ATP (adenosine triphosphate) 4 mg / kg group, each with 10 animals .

[0057] The mice in groups (2) to (6) were fasted for 16 hours to create a closed bra...

Example Embodiment

[0060] Example 3

[0061] This example relates to the neuroprotective effect of p-hydroxybenzylidene acetone on mice with vascular dementia.

[0062] Medicines and laboratory equipment: p-Hydroxybenzylidene acetone: Dilute with 5% glucose injection to an appropriate concentration when used. Automatic recorder for jumping platform experiments, a product of the Institute of Medicine, Chinese Academy of Medical Sciences; a fluorescence spectrophotometer, a product of HITACHI, Japan; a microplate reader.

[0063] Experimental animals: clean-grade Kunming mice, weighing 20-22g.

[0064] 1. The improvement effect of p-hydroxybenzylidene acetone on learning and memory dysfunction in cerebral ischemia-reperfusion mice

[0065] 50 mice were randomly divided into five groups: (1) sham operation group; (2) model group; (3) p-hydroxybenzylidene acetone 1 mg / kg group; (4) p-hydroxybenzylidene acetone 2 mg / kg group; (5) p-hydroxybenzylidene acetone 4 mg / kg group; 10 animals in each group.

[0066...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of p-hydroxy benzylidene acetone in preparation of drugs for preventing and/or treating encephalopathy, and particularly relates to the application of p-hydroxy benzylidene acetone in preparation of drugs for treating and/or preventing cerebral injury diseases or cerebrovascular diseases. The pharmacological research provided by the invention discovers that p-hydroxy benzylidene acetone has good treating function for cerebral ischemia and cerebral ischemia reperfusion injury when the p-hydroxy benzylidene acetone is applied to prepare drugs for treating cerebrovascular diseases. The research provided by the invention suggests that p-hydroxy benzylidene acetone is a compound with good treating effect and low toxic and adverse effects from the aspects of cerebral physiological function, nerve cell biochemistry and pathomorphology, has a better treating effect than the existing related drugs for treating cerebrovascular diseases, and is possibly developed into a new drug for treating cerebrovascular diseases, cerebral ischemia and cerebral ischemia reperfusion injury and cerebral injury.

Description

technical field [0001] The invention relates to a new application of p-hydroxybenzylideneacetone, in particular to the application of p-hydroxybenzylideneacetone in the preparation of drugs for preventing and / or treating encephalopathy. Background technique [0002] Encephalopathy refers to any organic brain damage, which is a disease of brain nerve tissue damage caused by genetics, congenital brain hypoplasia, brain trauma, brain tumors, cerebral hemorrhage, cerebral infarction, infection, and chemical drug poisoning. Common encephalopathy can be divided into three categories: one is children with cerebral palsy and mental retardation caused by heredity and congenital dysplasia; Chronic degenerative diseases in which nerve fiber damage leads to aging and degeneration of brain nerve cells, including Alzheimer's disease, brain atrophy, Parkinson's disease, etc. [0003] Throughout all kinds of encephalopathy, due to the blockage of nerve information transmission channel (bra...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/12A61P9/00A61P9/10A61P25/00
Inventor 李茹冰吴新荣李健孙智平陈新季波袁进黄涛阳
Owner GUANGZHOU GENERAL HOSPITAL OF GUANGZHOU MILITARY COMMAND
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap